<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900704</url>
  </required_header>
  <id_info>
    <org_study_id>SPC-SER120-DB4-201301</org_study_id>
    <nct_id>NCT01900704</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4</brief_title>
  <acronym>DB4</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serenity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Serenity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of SER120 nasal spray formulations in patients with
      nocturia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of nocturic episodes at the end of treatment compare to prior to treatment</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes on the treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">891</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>SER120 750 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 750 ng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SER120 1500 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 1500 ng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 750 ng</intervention_name>
    <description>SER120 750 ng</description>
    <arm_group_label>SER120 750 ng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 1500 ng</intervention_name>
    <description>SER120 1500 ng</description>
    <arm_group_label>SER120 1500 ng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female 50 years or older

          -  Nocturia of 6 or more months duration averaging greater than 2 nocturic episodes per
             night

        Exclusion Criteria:

          -  CHF

          -  Diabetis Insipidus

          -  Renal insufficiency

          -  Hepatic insufficiency

          -  Incontinence

          -  Illnesses requiring systemic steroids

          -  Malignancy within the past 5 years

          -  Sleep apnea

          -  Nephrotic syndrome

          -  Unexplained pelvic mass

          -  Urinary bladder neurological dysfunction

          -  Urinary bladder surgery or radiotherapy

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stephen M. Auerbach, MD</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <disposition_first_submitted>November 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 24, 2015</disposition_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

